{"id":"peripheral-blood-stem-cell-transplantation","safety":{"commonSideEffects":[{"rate":"high","effect":"Infection"},{"rate":"high","effect":"Bleeding"},{"rate":"medium","effect":"Graft-versus-host disease"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This process allows the bone marrow to produce healthy blood cells, reducing the risk of infection and bleeding. The transplanted stem cells can also help the body fight cancer by replacing damaged bone marrow cells.","oneSentence":"Peripheral blood stem cell transplantation involves the transfer of stem cells from the blood into the body to help the bone marrow recover after chemotherapy or radiation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:35.147Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various blood cancers, including leukemia and lymphoma"}]},"trialDetails":[{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","enrollment":94},{"nctId":"NCT05909202","phase":"NA","title":"A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients","status":"RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2024-06-05","conditions":"Neoplasm, Caregivers","enrollment":218},{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":"Acute Myeloid Leukemia","enrollment":244},{"nctId":"NCT07020533","phase":"PHASE1","title":"A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-05-08","conditions":"Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":46},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT04628026","phase":"PHASE3","title":"Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":650},{"nctId":"NCT01176006","phase":"PHASE2","title":"Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-05","conditions":"DOCK8 Deficiency","enrollment":70},{"nctId":"NCT01087294","phase":"PHASE1","title":"Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-08-04","conditions":"Leukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins","enrollment":85},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT05554419","phase":"PHASE2","title":"Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-01","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm","enrollment":184},{"nctId":"NCT04214249","phase":"PHASE2","title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-17","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":49},{"nctId":"NCT05463133","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-07-08","conditions":"Chronic Granulomatous Disease","enrollment":50},{"nctId":"NCT03173937","phase":"PHASE1, PHASE2","title":"Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2017-06-13","conditions":"Severe Aplastic Anemia, Hypo-Plastic MDS, Myelodysplastic Syndrome (MDS)","enrollment":37},{"nctId":"NCT07498465","phase":"PHASE1","title":"A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-09-10","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia","enrollment":29},{"nctId":"NCT04975698","phase":"PHASE2","title":"HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2021-10-25","conditions":"HIV Associated Lymphoma","enrollment":12},{"nctId":"NCT03533816","phase":"PHASE1","title":"Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2020-01-31","conditions":"Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia","enrollment":38},{"nctId":"NCT00576979","phase":"PHASE1, PHASE2","title":"Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2008-03-04","conditions":"Leukemia","enrollment":51},{"nctId":"NCT01453088","phase":"PHASE2","title":"Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2010-06-24","conditions":"Multiple Myeloma","enrollment":63},{"nctId":"NCT04464434","phase":"PHASE4","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-17","conditions":"Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma","enrollment":60},{"nctId":"NCT03910452","phase":"EARLY_PHASE1","title":"Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-10-28","conditions":"Chronic Granulomatous Disease","enrollment":4},{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":"GATA2, Immunodeficiency, MDS","enrollment":144},{"nctId":"NCT00106925","phase":"","title":"Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2005-04-22","conditions":"Graft-versus-leukemia, Graft vs Host Disease, Graft Rejection","enrollment":1000},{"nctId":"NCT06093867","phase":"","title":"Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2024-04-08","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":40},{"nctId":"NCT03267433","phase":"PHASE3","title":"Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2017-11-27","conditions":"Mantle Cell Lymphoma","enrollment":689},{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT06816134","phase":"PHASE2","title":"Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-01-30","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell","enrollment":48},{"nctId":"NCT01011920","phase":"PHASE2","title":"Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2009-11","conditions":"Central Nervous System Lymphoma","enrollment":227},{"nctId":"NCT03520647","phase":"PHASE2","title":"Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2019-02-19","conditions":"Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":56},{"nctId":"NCT04904588","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2021-09-30","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia","enrollment":300},{"nctId":"NCT03835312","phase":"NA","title":"Sequential Transplantation of UCBSCs and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency T1DM","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2019-02-20","conditions":"Diabetes Mellitus, Type 1, Immunologic Deficiency Syndromes","enrollment":50},{"nctId":"NCT03663933","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-04","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders","enrollment":71},{"nctId":"NCT06705062","phase":"PHASE3","title":"Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Cell Transplant, Graft Versus Host Disease","enrollment":316},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT05011422","phase":"PHASE1","title":"Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-11-03","conditions":"Pediatric Hematologic Malignancies","enrollment":50},{"nctId":"NCT00107289","phase":"PHASE2","title":"Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-05","conditions":"Neuroblastoma, Pheochromocytoma","enrollment":200},{"nctId":"NCT04579523","phase":"PHASE1","title":"²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-06-01","conditions":"Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT07269041","phase":"PHASE1, PHASE2","title":"Immune Tolerance Induction After Liver Transplantation","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2026-02-20","conditions":"Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects","enrollment":12},{"nctId":"NCT04829136","phase":"NA","title":"Sustained Oral Fiber Supplementation for Patients Undergoing Donor Stem Cell Transplantation for Hematological Malignancies","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-06-22","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":30},{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT05357482","phase":"PHASE1, PHASE2","title":"Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-05-12","conditions":"Sickle Cell Anemia, Beta Thalassemia","enrollment":40},{"nctId":"NCT03980769","phase":"PHASE2","title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-05-05","conditions":"Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder","enrollment":40},{"nctId":"NCT06752694","phase":"PHASE2","title":"Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-25","conditions":"Aplastic Anemia","enrollment":20},{"nctId":"NCT06345495","phase":"PHASE2","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-01","conditions":"Splenomegaly, Myelofibrosis","enrollment":30},{"nctId":"NCT05236062","phase":"NA","title":"Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2022-04-14","conditions":"Graft Vs Host Disease, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease","enrollment":36},{"nctId":"NCT03587272","phase":"PHASE2","title":"Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease","status":"RECRUITING","sponsor":"Robert Nickel","startDate":"2018-04-17","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT06059391","phase":"PHASE2","title":"CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-12","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia","enrollment":216},{"nctId":"NCT06316856","phase":"PHASE1, PHASE2","title":"CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2024-06-18","conditions":"T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia","enrollment":54},{"nctId":"NCT07462962","phase":"","title":"Effects of Mindfulness Meditation Training on Anxiety and Sleep Quality of Patients With Hematopoietic Stem Cell Transplantation During Admission in the Laminar Flow Chamber","status":"COMPLETED","sponsor":"Henan University","startDate":"2025-03-01","conditions":"Hematopoietic Stem Cell Transplantation (HSCT), Cancer and / or Hematological Malignancy","enrollment":70},{"nctId":"NCT06856226","phase":"","title":"Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-04","conditions":"Leukemia, Lymphoma, Hematologic Malignancy","enrollment":88},{"nctId":"NCT06326008","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2026-03-15","conditions":"B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse","enrollment":48},{"nctId":"NCT07458854","phase":"NA","title":"Exercise in Patients Undergoing Autologous Stem Cell Transplantation: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"TC Erciyes University","startDate":"2014-10-14","conditions":"Hematologic Malignacy, Autologous Hematopoietic Stem Cell Transplantation","enrollment":15},{"nctId":"NCT04965597","phase":"PHASE2","title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-04-19","conditions":"Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia","enrollment":40},{"nctId":"NCT07225985","phase":"PHASE1, PHASE2","title":"Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-05-01","conditions":"Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma","enrollment":50},{"nctId":"NCT05540340","phase":"PHASE1","title":"A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-09-09","conditions":"Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell","enrollment":39},{"nctId":"NCT07455500","phase":"NA","title":"Study of an Innovative Therapy Using CAR-T Cells Targeting IL-1RAP in Patients With High-Risk Myelodysplastic Syndromes (MDS","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2026-05","conditions":"Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT02629120","phase":"PHASE1, PHASE2","title":"High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-17","conditions":"Chronic Granulomatous Disease Transplant","enrollment":45},{"nctId":"NCT04375631","phase":"PHASE1","title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-03","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT03652441","phase":"PHASE2","title":"Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2019-11-13","conditions":"Classical Hodgkin Lymphoma","enrollment":14},{"nctId":"NCT03541889","phase":"PHASE1","title":"REVEAL Biomarkers of Engraftment After Alternative Donor HSCT","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2021-02-05","conditions":"Primary Graft Failure","enrollment":56},{"nctId":"NCT01520623","phase":"NA","title":"Complement and Graft-versus-host Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-04","conditions":"Allografted With Myeloablative Conditioning","enrollment":70},{"nctId":"NCT04914338","phase":"NA","title":"A Multidisciplinary Approach to Improve the Health of Older Adults With Blood Cancers After Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-06-03","conditions":"Hematopoietic and Lymphoid Cell Neoplasm","enrollment":40},{"nctId":"NCT05316701","phase":"PHASE3","title":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orca Biosystems, Inc.","startDate":"2022-06-21","conditions":"Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":187},{"nctId":"NCT02333162","phase":"PHASE1","title":"Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2014-12-05","conditions":"Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT05617625","phase":"PHASE2","title":"CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome","status":"SUSPENDED","sponsor":"Guenther Koehne","startDate":"2026-06","conditions":"Myelodysplastic Syndromes, Graft Vs Host Disease, Graft-versus-host-disease","enrollment":50},{"nctId":"NCT07285668","phase":"NA","title":"Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-02-26","conditions":"Hematologic Malignancies","enrollment":38},{"nctId":"NCT04195633","phase":"PHASE2","title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-01-25","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT00716066","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-06","conditions":"Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune","enrollment":53},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT02730299","phase":"PHASE3","title":"Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS","status":"COMPLETED","sponsor":"Gamida Cell ltd","startDate":"2016-12-16","conditions":"Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML)","enrollment":125},{"nctId":"NCT03924401","phase":"PHASE2","title":"Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2019-08-22","conditions":"Graft Versus Host Disease","enrollment":30},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT03850366","phase":"PHASE2","title":"HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib","status":"RECRUITING","sponsor":"Henry Ford Health System","startDate":"2016-03-08","conditions":"Hematological Malignancy","enrollment":15},{"nctId":"NCT05711667","phase":"PHASE3","title":"A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2024-07-11","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":105},{"nctId":"NCT04684368","phase":"PHASE2","title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2021-07-13","conditions":"Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma","enrollment":160},{"nctId":"NCT05432635","phase":"PHASE1","title":"Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-08-01","conditions":"B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma","enrollment":15},{"nctId":"NCT03802695","phase":"PHASE1","title":"A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","status":"RECRUITING","sponsor":"Orca Biosystems, Inc.","startDate":"2019-04-08","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia","enrollment":300},{"nctId":"NCT05664126","phase":"PHASE2","title":"Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-08-01","conditions":"Cytomegalovirus, Adenovirus","enrollment":42},{"nctId":"NCT00003042","phase":"PHASE2","title":"Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"1997-05-30","conditions":"Breast Cancer","enrollment":41},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT07228624","phase":"PHASE2","title":"Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-02-04","conditions":"Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":50},{"nctId":"NCT01203722","phase":"PHASE1, PHASE2","title":"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-09","conditions":"Hematologic Malignancies","enrollment":87},{"nctId":"NCT06679829","phase":"PHASE2","title":"A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-11-06","conditions":"Multiple Myeloma","enrollment":215},{"nctId":"NCT02867384","phase":"PHASE2","title":"Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-11-29","conditions":"Graft vs. Host Disease","enrollment":181},{"nctId":"NCT06207799","phase":"PHASE2","title":"Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-17","conditions":"Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging","enrollment":40},{"nctId":"NCT03480360","phase":"PHASE3","title":"Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2018-03-28","conditions":"Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia","enrollment":21},{"nctId":"NCT06731036","phase":"","title":"Expanded Access to CD34+ Selection Utilizing Miltenyi CliniMACS Prodigy® for Patients Receiving Peripheral Blood Stem Cell Transplantations and Stem Cell Boosts","status":"AVAILABLE","sponsor":"University of Florida","startDate":"","conditions":"Severe Combined Immunodeficiency, Fanconi Anemia, Dyskeratosis Congenita","enrollment":""},{"nctId":"NCT02861417","phase":"PHASE2","title":"Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-08-05","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome","enrollment":204},{"nctId":"NCT03600155","phase":"PHASE1","title":"Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-10-11","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":29},{"nctId":"NCT05393804","phase":"PHASE2","title":"A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-05-20","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT03619551","phase":"PHASE2","title":"Conditioning SCID Infants Diagnosed Early","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2018-10-22","conditions":"SCID","enrollment":56},{"nctId":"NCT03467386","phase":"PHASE1","title":"Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2018-03-19","conditions":"Acute Myeloid Leukemia","enrollment":56},{"nctId":"NCT05600426","phase":"PHASE3","title":"A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2023-01-25","conditions":"Severe Aplastic Anemia","enrollment":53},{"nctId":"NCT04761770","phase":"PHASE2","title":"Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-02-15","conditions":"Myelodysplastic Syndrome, Myeloproliferative Neoplasms, Chronic Myelomonocytic Leukemia","enrollment":33},{"nctId":"NCT04328714","phase":"PHASE1","title":"Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease","status":"TERMINATED","sponsor":"Edwin Horwitz","startDate":"2021-12-02","conditions":"Acute Leukemia, Myelodysplastic Syndromes","enrollment":4},{"nctId":"NCT07410520","phase":"PHASE2","title":"PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-07","conditions":"Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)","enrollment":50},{"nctId":"NCT03165851","phase":"","title":"Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2005-04-10","conditions":"Acute Myeloid Leukemia, Pediatric","enrollment":320},{"nctId":"NCT04806347","phase":"PHASE1","title":"Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults","status":"NOT_YET_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Blood Disease","enrollment":12},{"nctId":"NCT07392970","phase":"PHASE2","title":"Motixafortide for MRD Sensitization in AML","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-31","conditions":"Acute Myeloid Leukemia, Measurable Residual Disease","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PBPC transplantation","PBSC transplantation","peripheral blood progenitor cell transplantation","transplantation","peripheral blood stem cell"],"phase":"phase_3","status":"active","brandName":"peripheral blood stem cell transplantation","genericName":"peripheral blood stem cell transplantation","companyName":"Memorial Sloan Kettering Cancer Center","companyId":"memorial-sloan-kettering-cancer-center","modality":"Biologic","firstApprovalDate":"","aiSummary":"Peripheral blood stem cell transplantation involves the transfer of stem cells from the blood into the body to help the bone marrow recover after chemotherapy or radiation. Used for Treatment of various blood cancers, including leukemia and lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":37,"withResults":21},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}